Celularity Inc.
Investor Relations
About Celularity
Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a biotechnology company leading the next evolution in cellular and regenerative medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (MLASCs). These therapeutic programs target indications in cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Latest Press Releases
Events & Presentations
Celularity Investor Presentation
Last Updated June, 2022
Jefferies Cell and Genetic Medicine Summit
September 30, 2022, at 11:00 am ET
Celularity at Morgan Stanley 20th Annual Global Healthcare Conference
September 14, 2022, at 12:20 pm ET
Celularity at H.C. Wainwright 24th Annual Global Investment Conference
September 12, 2022, at 1:30 pm ET
Celularity at Oppenheimer 32nd Annual Healthcare Conference
March 17, 2022 at 11:20 AM
Celularity at Oppenheimer 32nd Annual Healthcare Conference
March 17, 2022 at 11:20 AM
Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement for Celularity’s Halal-certified Biomaterial Products
Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation
Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy